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Ewing sarcoma is a bone and cartilage cancer affecting children and 
adolescents. Up to 90% of Ewing sarcoma patients express a chimeric EWS/FLI1 
protein which is formed by a chromosomal translocation, and is known to induce 
aberrant transcription, bind with endogenous EWS and cause mitotic defects similar to 
knockdown of EWS. In EWS knockout studies, EWS-/- mice produce smaller pups with 
shorter, brittle bones compared to wild-type littermates suggesting EWS has a role in 
skeletal and overall development. Since Ewing’s sarcoma develops in the bone, the role 
of endogenous EWS is of interest as it may provide an insight into the parthenogenesis 
of this disease. To investigate this we generated a maternal zygotic (MZ) ewsa null 
mutant zebrafish, produced by insertional mutagenesis. Chondrocyte maturation begins 
after mesenchymal condensation at about 3 days past fertilization (dpf), then cells 
undergo morphological changes by 4dpf to become prehypertrophic chondrocytes with 
most fully differentiated into hypertrophic chondrocytes by 6dpf. Previously, we reported 
that Ewsa modulates the mRNA expression of target genes of transcription factor Sox9, 
the master transcriptional regulator of chondrocyte differentiation. Given the regulatory 
role of Sox9 in chondrogenesis, an important question is whether Ewsa directly 
regulates the expression level of Sox9 proteins. Thus, we generated antibodies against 
Sox9a and Sox9b, and performed immunohistochemistry in 3-6dpf of wt/wt and MZ 
ewsa/ewsa zebrafish mutants.  As a result, Sox9a localized in the nucleus, and the 
expression levels of Sox9a proteins were unchanged among 3-6dpf wt/wt and MZ 
ewsa/ewsa zebrafish mutants. This suggests that Sox9a protein is not regulated by 
Ewsa during chondrocyte maturation. One upregulated Sox9 target gene was 
	   iv	  
connective tissue growth factor (ctgf). Ctgf is known to have a critical role in 
endochondral ossification, furthermore the overexpression of Ctgf regulation results in 
skeletal defects and reduced hypertrophy. We suspect that Ews regulates Ctgf during 
endochonral ossification and aim to confirm this in this study. We discovered that Ctgf is 
overexpressed in craniofacial cartilage of mutant embryos at 4dpf and 6dpf. Also 
measurements of cartilage structures show evidence of skeletal defects in these 
embryos as early as 4dpf. This is evidence that the regulation of Ctgf by Ewsa is 
essential for normal chondrocyte maturation and skeletal development. In addition, a 
reduction of ctgfa signal in situ and Ctgf in immunohistochemistry assays was observed 
in the vascular structures in mutant embryos at 3dpf and 6dpf suggesting Ewsa may 
regulate ctgf expression in vascular tissue. Which is important since vascular invasion 
into mature chondrocytes is necessary in skeletal development. In summary, we 
discovered that Ewsa may regulate stage-specific, and tissue specific expression of 
Ctgf during embryonic development. Understanding the pathway of Ewsa-dependent 
skeletogenesis may supply a platform for the molecular pathogenesis of Ewing 
sarcoma. 
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Ewing’s sarcoma (ES) is a bone cancer usually affecting children and 
adolescents. One hallmark of Ewing’s tumors is that patients express an 
aberrant oncogenic fusion protein which consists of the N-terminal domain of 
the Ewing’s sarcoma protein (EWS) and the C-terminal domain of an ETS 
transcription factor [1]. The fusion protein is produced due to a translocation 
event which involves specific breakpoints in genetic coding regions for both 
of the proteins [2]. The most common fusion protein, which is reported in 
90% of Ewing’s sarcoma patients is EWS/FLI1 [3]. EWS/FLI1 can act as a 
transcription factor and can interact with the spliceosome machinery to 
produce altered splicing events [4]. Also EWF/FLI1 can interact with 
endogenous EWS thus possibly interfering with normal endogenous function 
[5]. Lastly, the knockdown of EWS causes mitotic defects and genomic 
instability in human cells similar to the phenotype seen in EWS/FLI1 
expressing cells, thus suggesting a reduction of endogenous EWS function in 
the presence of EWS/FLI1 [5, 6]. The study of the fusion protein 
demonstrates a gain of function within the context of this disease but there 
still remains the possibility of a loss of function in terms of EWS 
haploinsufficiency, or inhibition of endogenous EWS function.  
Given that EWS function could be effected by EWS/FLI1 which is found 
in ES patients, and since the tumors arise in the developing bone, the role of 
EWS in skeletal development must be investigated. Knockout mice for EWS 
exhibited 90% postnatal lethality, pups were smaller, and had less bone 
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density than wild-type littermates [7].  Although the mechanisms for this 
phenotype were not explored, this suggests that EWS is involved in bone 
development. Long bones develop through endochondral ossification; the 
process of chondrogenesis lays down cartilage with later calcification of the 
tissue giving rise to mature bone. Chondrogenesis begins with mesenchymal 
condensations at about 2dpf (days past fertilization) in zebrafish. The cells 
then undergo highly regulated transcriptional and morphological changes that 
promote progression from a proliferative and undifferentiated state into an 
intermediate or prehypertophic state by about 3dpf, [8],  and eventually they 
further differentiate into hypertrophic chondrocytes by 6dpf [9]. A recent 
report from our group shows that in a zebrafish model, MZ ewsa/ewsa mutant 
fish had significant facial cartilage deformations at 4dpf indicating that ewsa 
regulates chondrocyte maturation. This same report also elucidated a 
biochemical interaction between EWS and SRY (Sex Determining Region Y)-
Box 9 (SOX9)[10].  The transcription factor SOX9 has been dubbed the 
“master regulator” of chondrogenesis due to its essential role in the process 
and since the transcriptional targets of SOX9 are involved in chondrocyte 
maturation [11]. In vivo knockdown or knockout of SOX9 results in mice with 
severe skeletal defects and elimination of SOX9 target gene expression [12]. 
In our previous study, we reported 8 of the 30 SOX9 target genes tested 
were modulated in MZ ewsa/ewsa mutant embryos at 27hpf, thus suggesting 
that EWS regulates skeletal development by modulating the targets of SOX9 
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[10]. Yet it is not known if Sox9 expression is being affected by Ewsa, which 
in turn would explain the changes in targets of Sox9.  
One of the target genes of Sox9 upregulated with the loss of ewsa is 
connective tissue growth factor (ctgf). CTGF is of interest as it is involved in 
many processes including extracellular matrix (ECM) production, 
chondrogenesis, proliferation, apoptosis, and angiogenesis [13]. The ECM is 
essential for normal development by serving as scaffolding and signaling. 
Mutations in genes for ECM components can lead to severe skeletal defects 
and fibrosis [14].  Transgeneic mice overexpressing CTGF exhibited smaller 
stature, increased expression of ECM components, increased chondrocyte 
proliferation, and shorter hypertrophic zones in the bones of embryos as 
compared to wild type littermates [15-17].  Indeed, in our previous study MZ 
ewsa/ewsa embryos had shorter hypertrophic zones in the facial cartilage, 
which also develops through endochondral ossification, and a higher number 
of chondrocytes when compared to the wild type [10]. Given the importance 
of CTGF in this process, and given the phenotype observed in our mutants, 
the possibility of EWS regulation of CTGF during normal endochondral 
ossification warrants investigation. Furthermore, the final stages of 
endochondral ossification require vascular invasion into the mature cartilage 
before calcification. CTGF has been shown to induce proliferation and 
migration of endothelial cells, and to promote production of vascular 
endothelial growth factor (VEGF) [18], a key signaling molecule promoting 
vascular endothelial growth, but at higher expression levels, CTGF binds to 
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and inhibits VEGF [19]. Therefore strict control of CTGF expression levels is 
imperative for normal angiogenesis, yet there have been no reports 
describing EWS as the regulatory protein in this process. 
In this report, to further investigate the regulatory role of EWS in 
chondrogenesis we focus on the temporal effect of EWS regulation of SOX9 
first of all, then focus on EWS regulation of Ctgf, both over the course of 
chondrocyte maturation. This will elucidate the role of EWS in the regulation 
of CTGF during chondrocyte maturation and to answer the questions; is 
CTGF regulation accomplished though regulation of SOX9 expression? Also, 
is the protein expression of CTGF regulated by EWS during chondrogenesis? 
Furthermore we hope to elucidate a regulatory role of EWS in endothelial 
expression of Sox9 and Ctgf. Since CTGF is involved in chondrogenesis and 
ECM production as well as angiogenesis, it would be expected that the 
misregulation of CTGF would lead to skeletal defects and inhibited vascular 
invasion into bone. Therefore in this report we use MZ ewsa/ewsa zebrafish 
to demonstrate the regulation of CTGF by EWS in chondrocyte maturation. 
Furthermore this report is the first to implicate EWS regulation of CTGF in 
vascular endothelial cells, and this may help in illuminating the mechanism 
by which misregulation of chondrocyte maturation proteins could contribute 
to the formation of Ewing’s sarcoma. 
  
	   5	  
 
 




Zebrafish families were bred and maintained at 28.5oC using an automatic 
filtration system from Aquatic Eco-Systems Inc, and embryos were staged as 
previously described [20]. The wild type line used was the Oregon AB line. 
The ewsa/ewsa line was generated by insertional mutagenesis by Znomics 
Inc, and is maintained as a Maternal Zygotic (MZ) line in our system. 
 
Immunohistochemistry 
Embryos were visualized as previously described [6]. Fixed embryos were 
permeabilized with methanol at -20oC overnight, digested with 0.01% trypsin 
(5min for 3dpf, 6min for 4dpf, 8min for 5dpf, 10min for 6dpf), and then 
blocked with blocking solution (10% fetal bovine serum, 1% dimethyl 
sulfoxide, 0.1% triton x- 100) for 1 hour. Primary antibodies were applied 
overnight at 4oC; embryos were washed thoroughly; and secondary 
antibodies were applied overnight at 4oC. Embryos were then washed 
thoroughly again, equilibrated to 50% glycerol, and stored in 100% glycerol. 
We used rabbit polyclonal antibodies for Sox9a or Sox9b (Pacific 
Immunology, CA) diluted 1:250 (1µL antibody into 250µL blocking solution) or 
1:500 (0.5µL antibody into 250µL blocking solution) and to visualize we used 
anti-rabbit Alexa 488 secondary antibody diluted 1:250 (1µL antibody into 
250µL blocking solution). We used a rabbit polyclonal anti-CTGF primary 
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antibody (ab6992 from abcam) diluted 1:1000 (0.5µL antibody into 500µL 
blocking solution) and anti-rabbit Alexa 488 secondary antibody diluted 1:250 
(1µL antibody into 250µL blocking solution) to visualize Ctgf. We also tested 
a rabbit polyclonal anti-CTGF primary antibody (07-1386 Millipore) diluted to 
1:1000 (0.5µL antibody into 500µL blocking solution) and anti-goat Alexa 594 
secondary antibody diluted 1:250 (1µL antibody into 250µL blocking solution) 
to visualize Ctgf. Images were taken with an Exi Aqua camera (Q Imaging) 
mounted on an Eclipse Ti microscope (Nikon). 
 
In situ hybridization 
In situ hybridization was performed as previously described [21]. Fixed 
embryos were bleached for 1 hour in a solution of 3%H2O2 / 0.5% KOH, 
washed in PBS, permeabilized in methanol at -20oC overnight, and then 
washed in PBS again. Embryos were digested with 0.01% trypsin (5min for 
3dpf, 6min for 4dpf, 8min for 5dpf, 10min for 6dpf) then equilibrated in HYB 
buffer at 60oC for 3 hours. Embryos were then hybridized overnight at 60oC 
with antisense RNA for ctgfa generated with T7 RNA polymerase and DIG-
labeled dUTP. Embryos were then treated with anti-DIG antibodies 
conjugated with alkaline phosphatase (AP) overnight at 4oC. After 
equilibration with AP buffer, signal was developed with BM Purple, washed 
with PBS, and then embryos were fixed again in 4% paraformaldehyde at 
room temperature for 30 minutes. 
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Statistics 
Statistical analysis was performed using Prism, version 5.03 (GraphPad 
Software Inc.). Welch’s t-test was used to compare ceratohyal cartilage 
dimensions between wild type and MZ ewsa/ewsa embryos. An unpaired t-
test was used to compare the number of Ctgf expressing cells in wild-type 








Zebrafish specific antibodies recognize Sox9a and Sox9b. Previous 
studies showed that sox9a mRNAs are expressed in cranial cartilages and 
somites [22], and sox9b mRNAs in notochord at early stages [23]. However, 
the local expression of zebrafish Sox9a and Sox9b proteins remains 
unknown. Thus, we generated antibodies specific to both zebrafish Sox9a 
and Sox9b. Recombinant proteins containing C-terminus of Sox9a (304-462 
amino acid), and of Sox9b (290-408 amino acid) were purified from E. coli, 
and was used as antigens for synthesis of polyclonal antibody in rabbit (fig. 
1A).  The C-terminus of Sox9a and Sox9b were specifically chosen to avoid 
cross-reactivity against the HMG-box in the N-terminus, which is universally 
conserved among Sox proteins. First, the reactivity of antibodies were 
optimized. Wild-type (wt/wt) zebrafish embryos at 3dpf were subjected to 
immunohistochemistry using either 1:250 or 1:500 dilutions of Sox9a and 
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Sox9b antibody (fig. 1B). Embryos stained with a 1:250 dilution of antibody 
had a high background when compared with embryos strained with a 1:500 
antibody dilution. The embryos stained with 1:250 dilution of antibodies 
displayed no coinciding tissue specific signals compared to the previous 
report, suggesting that there are high background signals in both samples. 
Therefore, wild-type embryos at 1dpf were stained with 1:500 dilution of 
either Sox9a or Sox9b antibodies (fig. 2). Sox9a signal was detected in the 
somites (fig. 2A, white arrows) with Sox9b being expressed only in the 
posterior of the notochord (fig. 2B). This data correlates with published 
sox9a and sox9b mRNA expression data suggesting a lack of post-
transcriptional regulation in the tissues where sox9a and sox9b are being 
expressed at 1dpf. 
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Figure 1. Zebrafish specific 
antibodies produced for Sox9a 
and Sox9b.  (A) The diagram 
shows zebrafish-specific 
antibodies against Sox9a and 
Sox9b designed to recognize the 
C-terminal domains. (B) 
Immunohistochemestry of wild-
type (WT) zebrafish 
embryos at 3dpf with 
1:250 and 1:500 
dilutions of Sox9a 
primary antibody 
show a more intense 
background signal in 
the 1:250 dilution than 
in the embryos 
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of wild-type embryos 
at 1dpf with and 
Sox9b. White arrows 
show Sox9a (A.) 
expressing regions in 
the anterior tail section 
somites. Staining by 
Sox9b (B.) did not 
produce similar signal 
in the somite region 
yet both Sox9a and 
Sox9b showed 
expression in most 
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Ewsa does not regulate the expression levels of Sox9a and Sox9b 
proteins in facial cartilage of zebrafish. Since Ewing Sarcoma arises in 
bone and Sox9 is essential for chondrocyte maturation [12], Sox9 expression 
and the expression of the genes it regulates is of interest. We have 
previously reported that Ewsa binds to Sox9 and Sox9 target genes were 
modulated in the ewsa MZ ewsa/ewsa embryos at 27hpf by qPCR [10]. Being 
that these are targets of Sox9, it is possible that any modulation of these 
targets are the result of expression modulation of their transcriptional 
regulator Sox9 during this stage of development. Furthermore, given the 
evolutionary genome duplication in the zebrafish which produced two 
homologs of many genes including sox9a and sox9b, the question is raised if 
Sox9b is involved in chondrocyte maturation as a redundant or compensatory 
mechanism to counteract any change in Sox9a expression. Therefore, we 
investigated whether the expression Sox9a and Sox9b proteins is altered in 
MZ ewsa/ewsa mutant compared to wt/wt zebrafish. By 2dpf neural crest 
derived mesenchymal cells condense to form the pharyngeal arches, the 
proliferative precursors to chondrocytes. At 3dpf, these cells start to 
differentiate into pre-hypertophic chondrocytes. These cells further undergo 
morphological changes from small and round cells to long columnar cells 
called hypertrophic cells, and these cells align in the cartilage structure 
through intercalation (conversion extension) [24].  To determine whether the 
expression of Sox9a and Sox9b proteins are regulated by Ewsa in facial 
cartilage, wt/wt and MZ ewsa/ewsa zebrafish embryos were harvested at 3-
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6dpf, and  subjected to immunohistochemistry using Sox9a or Sox9b 
antibodies (figs. 3,4,15-19).  At 3dpf (fig. 3), there was no difference in the 
percentage of embryos expressing Sox9a signal between wt/wt and MZ 
ewsa/ewsa in both the Meckel’s cartilage and ceratohyal cartilage. 
Furthermore, the Sox9a signal was localized to the nucleus. In addition, 
consistent with a previous report [22], there was no Sox9b (fig.4) signal in 
both wt/wt and MZ ewsa/ewsa embryos. This data suggests that Sox9b does 
not play a redundant role of Sox9a in the Meckel’s cartilage and ceratohyal 
cartilage. This trend continued 4dpf to 6dpf (figs.18,19). Overall, Ewsa does 
not regulate the expression level of Sox9a and Sox9b expression during 




Figure 3. Sox9a expressed in wild-type and mutant embryo facial cartilage.  
Immunohistochemistry of wild-type (WT) and maternal zygotic (MZ) mutant Meckel’s 
cartilage and ceratohyal cartilage at 3dpf with anti-Sox9a antibodies show that 100% of 
the WT and 100% of the MZ embryos tested expressed Sox9a in both the Meckel’s 
cartilage and ceratohyal cartilage. 6 WT and 3 MZ embryos total. Antibody dilution 
1:500. 
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Figure 4. Sox9b not expressed in wild-type or mutant embryo facial cartilage.  
Immunohistochemistry of wild-type (WT) and maternal zygotic (MZ) mutant Meckel’s 
cartilage and ceratohyal cartilage at 3dpf with anti-Sox9b antibodies show that in 100% 
of both WT and MZ embryos lack expression of Sox9b. 5 WT and 5 MZ embryos total 
Antibody dilution 1:500. 
 
 
Cartilage deformation in MZ ewsa/ewsa embryos occurs during 
chondrocyte maturation. Previously we have described several craniofacial 
deformations which occur in adult MZ ewsa/ewsa zebrafish. The exact time in 
embryonic development when these deformations begin to appear is not 
known. To answer this we began by measuring the length and width of the 
ceratohyal cartilage in MZ ewsa/ewsa embryos and compared to those taken 
from wt/wt embryos that have been stained with wheat germ agglutinin 
(WGA) as a marker for ECM (fig. 5A). At 4dpf, when compared to the wt/wt 
embryos the ceratohyal of the MZ ewsa/ewsa embryos did not significantly 
differ in length but were slightly wider (fig. 5B).  At 6dpf the width of the MZ 
ewsa/ewsa remained significantly shorter yet the degree of deformation 
severity was increased due to the wt/wt cartilage being significantly 
lengthened whereas the MZ ewsa/ewsa cartilage remained short (fig. 5C). 
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The timing of this deformation is significant since it is occurring during a 
critical time period of chondrocyte maturation. Yet since the cartilage was 
already significantly wider at 4dpf, the beginning stages of the deformation 
must begin earlier with the mechanism causing the deformation occurring at 
an even earlier stage of development. 
Figure 5. Cartilage deformation seen in 
MZ ewsa mutant cartilage. The length 
and width of ceratohyal cartilages taken 
from WT and MZ embryos were measured 
at their widest and longest points as 
shown in A. At 4dpf (B), there was no 
difference in the length of the ceratohyal 
between the WT and MZ tissues however, 
the width of the MZ ceratohyal was 
significantly greater than that of the WT. 
The deformation became more severe at 
6dpf (C) as the width of the MZ remained significantly greater yet the length of the MZ 
ceratohyal did not increase as did the WT ceratohyal thus making it signifigantly shorter 
than WT. Measured with Image J, units are in pixels. 
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Optimization of commercial CTGF antibodies in zebrafish. As we 
previously reported, the loss of ewsa induces the upregulation of ctgfa at 
27hpf but the protein expression pattern for Ctgf remains unclear. To monitor 
Ctgf expression in zebrafish embryos during development, we tested 
commercially available antibodies against human CTGF. The epitope 
sequence of the Abcam anti-CTGF antibody (ab6992) produced in rabbit 
corresponded to amino acids 223-348 of mouse CTGF and had an 83% 
identity with zebrafish Ctgfa and 62% with Ctgfb. The second antibody tested 
from Milipore (07-1386) was produced in goat and was against human CTGF 
with the epitope sequence corresponding to amino acids 27-349 and had a 
78% identity with zebrafish Ctgfa and 58% with Ctgfb. wt/wt embryos at 5dpf 
were stained with both antibodies. Both the goat and rabbit antibodies 
stained chondrocytes within the Meckel’s cartilage (fig. 6A). Full length Ctgf 
is approximately 40 kDa but it has been reported that Ctgf is rapidly cleaved 
by plasmin into either a 21 kDa or a 28 kDa fragments [25]. In a western blot 
analysis, both of the α-CTGF antibodies recognized zebrafish Ctgf in lysate 
from wt/wt zebrafish 6dpf (fig.9B) at approximately 40 kDa with the Abcam 
antibody and with the Millipore antibody two fragments were found at 28 kDa 
and 21 kDa possibly recognizing a cleaved version of Ctgf. To validate 
whether the signals obtained from immunohistochemistry are specific to 
Ctgfa, in situ hybridization using antisense RNA probes for ctgfa mRNA was 
performed using 3dpf wt/wt embryos (fig.7). In situ hybridization revealed 
that ctgfa mRNA expresses in facial cartilage. This correlates with the signal 
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detected in the α-CTGF IHC assay above. The co-localization of antibody 
signal on structures that also expresses ctgfa mRNA helps to validate both of 
these antibodies for use in detecting Ctgf in zebrafish.  
Figure 6. Anti-Human Ctgf antibodies recognize ZF Ctgf.  (A) Immunohistochemistry 
of wild-type embryos at 5dpf using rabbit α-Ctgf and goat α-Ctgf antibodies, signal 
colocalization shown in Meckel’s cartilage,(B) Western blot analysis of 6dpf zebrafish 
embryo lysate probed with the antibody from Millipore (goat α-ctgf) against Ctgf gives 
signal at ~40Kda where full-length Ctgf is expected as well as two bands at 28Kda and 
21Kda where cleaved Ctgf would be expected. The antibody from ABcam (rabbit α-ctgf) 
provided a band at the expected size as well as a prominent non-specific band. IHC; 
both antibodies 1:1000 dillution. WB; 1° Ab 1:200, 2° Ab 1:100,000.  
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Figure 7. Ctgf expression confirmed in wild-type vasculature and facial cartilage.  
In situ hybridization with probes for zebrafish ctgfa show expression of transcripts in 
vasculature and facial cartilage in WT embryos at 3dpf. ep, emthmoid plate; m, Meckel’s 
cartilage; isv, intersegmental vessels; da, dorsal aorta; pcv, posterior cardinal vein; ca, 
caudal artery; cv caudal vein. 
 
 
Ewsa inhibits the expression of Ctgfa protein in prehypertrophic 
chondrocytes at 4dpf and 6dpf. A previous study showed that in transgenic 
mice, overexpression of CTGF leads to shorter hypertrophic zones [15] 
suggesting that these chondrocytes undergo a delay of differentiation into 
the hypertrophic state. Because our previous study showed that the 
expression level of ctgfa mRNA is increased in MZ ewsa/ewsa compared to 
wt/wt at 27hpf [10], we further extended our study to investigate how Ctgfa 
protein is regulated during chondorgenesis. Immunohistochemistry was 
conducted on wt/wt and MZ ewsa/ewsa embryos at 4dpf and at 6dpf; the time 
span between 4dpf and 6dpf is when chondrocytes mature from 
prehypertophic into hypertophic chondrocytes. At 4dpf the number of 
chondrocytes in the MZ ewsa/ewsa Meckel’s cartilages expressing Ctgf were 
significantly higher than chondrocytes in wt/wt Meckel’s cartilage (fig. 8A), 
this was also the case with the ceratohyal cartilage (fig. 8B). Although a 
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similar trend was observed in the hyomandibular and palatoquadrate 
cartilages (fig. 20), the 3-D dimensionality of the structure made 
quantification technically challenging. Likewise, at 6dpf the number of 
chondrocytes in the MZ Meckel’s cartilages expressing Ctgf were 
significantly higher than chondrocytes in wt/wt Meckel’s cartilage (fig. 9A), 
again this was also the case with the ceratohyal cartilage (fig. 9B). Similar to 
the previous data, the trend for greater number of chondrocyte Ctgf 
expression was observed in the hyomandibular and palatoquadrate cartilages 
(fig .21). This data suggests that Ewsa inhibits Ctgf in chondrocytes during a 
critical period of differentiation and this negative regulation is essential for 
proper cartilage formation. 
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Figure 8. Ctgf is overexpressed in MZ ewsa mutant facial cartilage at 4dpf. 
Immunohistochemistry of wild-type (WT) and maternal zygotic (MZ) mutant Meckel’s 
cartilage (A) and ceratohyal cartilage (B) at 4dpf show a significantly increased number 
of chondrocytes expressing Ctgf in MZ cartilage than in WT tissue. Antibody dilution 
1:1000. 
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Figure 9. Ctgf is overexpressed in MZ ewsa mutant facial cartilage at 6dpf. 
Immunohistochemistry of wild-type (WT) and maternal zygotic (MZ) mutant Meckel’s 
cartilage (A) and ceratohyal cartilage (B) at 6dpf show continued increase in the number 




Ewsa regulates the expression of Ctgfa at vascular endothelial tissue in 
4dpf zebrafish embryos. Recently CTGF has been shown to play a role in 
basal lamia production in endothelium with severe vascular defects and 
embryonic lethality in CTGF knockout mice [26]. Studies of ctgfa expression 
in wild-type zebrafish embryonic vasculature at 90hpf showed ctgfa 
transcription occurring in the dorsal aorta, caudal artery and caudal veins 
[27]. As shown previously, ctgfa is also expressed in the intersegmental 
vessels (ISV) (fig. 7). Based on our previous report, it is highly possible that 
Ewsa-dependent regulation of Ctgf is required for angiogenesis. To elucidate 
this possibility, in situ hybridization was performed on wt/wt and MZ 
ewsa/ewsa embryos at 4dpf. In the results above, ctgfa mRNA was 
overexpressed in craniofacial cartilage 4dpf of MZ ewsa/ewsa MZ 
ewsa/ewsa. However unexpectedly in MZ ewsa/ewsa vasculature, there is 
not any evidence of ctgfa overexpression (fig. 10A) and was marked by either 
a loss of signal or possibly a loss of vascular structure. Therefore the 
changes were measured by counting the number of ISV with the similar 
degree of signal loss (fig. 10B). Normal ISVs consisted of approximately 
100% of the vessel expressing ctgfa, ISVs designated as “I” had 
approximately 75% of the vessel showing signal, “II” had approximately 25% 
-50%, “III” were less than approximately 25% of the vessel with a signal, and 
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“IV” were vessels that were not showing any signal. Wild-type embryos had 
significantly higher normal ISVs on average than the mutants which had a 
significantly higher number of ISVs of the type IV, or “missing” designation. 
Immunohistochemistry was performed on wt/wt and MZ ewsa/ewsa embryos 
also at 4dpf using α-Ctgf antibodies and ISVs were scored in the same 
manner as above (fig. 11). Similar to the above, wt/wt embryos averaged 
significantly more “normal” Ctgf signal in ISVs than did the mutants and 
likewise the mutants showed significant abnormal Ctgf expression in the ISV. 
Although the signal is modulated in MZ ewsa/ewsa vasculature, it is unclear 
whether this indicates a reduction in ctgfa mRNA and Ctgf protein being 
expressed in the axial vasculature or if there is an absence of vasculature all 
together. Regardless, this is evidence that Ewsa is critical for normal 
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Figure 10. Disruption 
of ctgfa mRNA 
expression 
patterning in MZ 
ewsa vasculature 
evident at 4dpf.  In 
situ hybridization with 
probes for zebrafish 
ctgfa show expression 
of ctgfa transcripts in 
vasculature at 4dpf (A). 




upregulated in the 
mutant embryos.  
However, MZ mutant ctgfa transcription is 
reduced in the posterior cardinal vein 
(yellow arrowhead), the intersegmental 
vessels (white arrow), the caudal artery 
(yellow arrow), and the caudal vein (white 
arrowhead). There are a significantly 
greater number of severely incomplete (IV) 
ISV in the MZ embryos, by comparison 
there are a significantly greater average 
number of normal ISV in the WT embryos 
(B). Score is average ISV per embryo, WT 
and MZ n=5 embryos, p≤0.001.   
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Figure 11. Expression pattern of Ctgf is perturbed in MZ ewsa mutant vasculature 
at 4dpf. Immunohistochemistry of WT and MZ embryos at 4dpf with anti-Ctgf antibodies 
(A). When compared to WT, MZ ebryos stained with anti-Ctgf showed a significant shift 
in the expression pattern of Ctgf in intersegmental vessels (B). White arrows show 
“normal” expression pattern in ISV of wild-type embryos. 
 
 
Ewsa is essential for normal Sox9 and Ctgf expression in axial 
vasculature. Whereas ISVs develop by angiogenesis, the primary axial 
vasculature (dorsal aorta for example) are derived from mesodermal tissue 
via vasculogenesis [28, 29]. The role of SOX9 in this process is unclear but 
SOX9 regulation is essential for cartilage vascularization due to its ability to 
inhibit VEGF [29]. Since EWS is able to bind to SOX9 [10], the loss of EWS 
could lead to increased bioavailable SOX9, the inhibitor of VEGF and 
therefore inhibited angiogenesis. To test any modulations of Sox9 
expression, immunohistochemistry on wt/wt and MZ ewsa/ewsa embryos at 
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3dpf and 6dpf was conducted with zebrafish Sox9a-specific antibodies (fig. 
12). Each embryo then had the dorsal aorta (DA) and posterior cardinal vein 
(PCV) scored for continuity starting with “cont” for a contiguous signal 
throughout the structure and “I” for one or two minor breaks in the continuity, 
“II” and “III” for increasing amount of breaks or severely large breaks, and 
“IV” for the structure missing any signal. At 3dpf the loss of ewsa yields a 
disruption in the Sox9a expression pattern of the MZ ewsa/ewsa embryonic 
DA in comparison to wt/wt, but this pattern disruption is not present in the 
PCV (fig. 12B). All of the wt/wt DA had continuous signal throughout the 
structure whereas by comparison the MZ ewsa/ewsa DA at 3dpf had breaks 
in the structure (Fig. 12B). Yet in mutants at 6dpf (fig. 13) both the DA and 
the PCV showed more severe breaks in Sox9a signal by comparison to wt/wt. 
This data suggests that Sox9a regulation in vascular development is stage 
and tissue specific, and is regulated by Ewsa. Likewise, to test if Ewsa 
modulates Ctgf expression in both the DA and PCV, embryos at 3dpf and 
6dpf were subjected to immunohistochemistry with anti-Ctgf antibodies (figs. 
12, 13). The Ctgf signal of MZ ewsa/ewsa embryos at 3dpf was reduced 
compared to wt/wt. This suggests that as a target of Sox9, Ctgf expression 
might be affected by a Ewsa-Sox9a interaction in these structures. Given that 
the response is not complete leaves the possibility of another mechanism 
regulating Ctgf expression. Given that Ctgf expression is nearly missing in 
wt/wt vasculature at 6dpf, and that in MZ ewsa/ewsa it seems to be 
maintained, wild type vasculature at 6dpf may be experiencing a 
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downregulation of Ctgf [30] in this tissue type. With ewsa as a regulatory 
element missing in mutants, the misregulation of Ctgfa could signal a 
developmental delay in the clearance of Ctgfa, therefore Ewsa may function 
to negative inhibition of Ctgfa in a tissue specific and temporal manner. 
 
Figure 12. Sox9a and Ctgf 
expression reduction in MZ ewsa 
mutant vascular endothelial tissue 
at 3dpf. Immunohistochemistry of WT 
and MZ embryos at 3dpf with anti-
Sox9a and anti-Ctgf antibodies (A) 
revealed that staining in the dorsal 
aorta (arrowhead) and posterior 
cardinal vein (arrow) of the MZ 
embryo tails contained breaks in 
signal. The embryos were rated for 
severity of discontinuity in signal from 
continuous (cont.) to missing (IV) (B). 
The loss of ewsa resulted in a 
reduction of endothelial expression of 
both Sox9 and Ctgf in the DA tissue, 
and loss of Ctgf in the PCV tissue. 
The exception to this reduction was 
Sox9 expression in the PCV which was increased. Sox9 WT and MZ; n=3. Ctgf WT, 
n=4; MZ, n=5.  
B 
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Figure 14. Sox9a expression 
reduced in MZ ewsa/ewsa mutants 
at 6dpf. (A), Torso sections of anti-
Sox9a or Ctgf stained 6dpf embryos 
showing the dorsal aorta (arrowhead) 
and posterior cardinal vein (arrow) in 
both wild-type and MZ ewsa mutant 
embryos. The embryos were rated for 
severity of discontinuity of each 
structure from continuous (cont.) to 
missing (IV) (B). The Sox9a signal in 
DAs and PCVs of WT embryos were 
mostly continuous whereas in the 
same structures in the MZ embryos 
the signal was reduced. Ctgf signal 
was reduced in both WT and MZ 
structures. Sox9; WT n=8, MZ n=3. 








The understanding of the role of EWS in early development has only 
recently begun to be explored. Previous studies in this lab have confirmed 
EWS involvement in skeletal development, yet the mechanisms of that role 
remain undiscovered. To investigate if EWS regulates chondrogenesis by 
regulating SOX9 transcription we looked at SOX9 protein levels through this 
process. Since Sox9 levels remained unchanged we next investigated the 
protein levels of Ctgf, a SOX9 target gene that is involved in chondrocyte 
maturation. Indeed we have found that both ctgf mRNA and Ctgf protein 
levels are higher in the cartilage of MZ ewsa/ewsa. Furthermore, skeletal 
defects in the MZ ewsa/ewsa mutant cartilage was observed. This suggests 
one way in which EWS regulates the process of endochondrial ossification is 
by regulating the expression of CTGF. 
In a previous report, the transcriptional targets of SOX9 were 
upregulated at 27hpf in MZ ewsa/ewsa [10], thus presenting the possibility 
that EWS is in fact regulating SOX9 expression and therefore the targets of 
SOX9. In this study we have found that, expression levels of Sox9a and 
Sox9b protein remained constant in the craniofacial cartilage of zebrafish 
embryos during the chondrocyte differentiation period and that Sox9b does 
not play a major role in this process. In this report, we discovered an 
increase in the number of cells expressing one of these transcriptional 
targets, Ctgf, in the craniofacial cartilage with the loss of ewsa. Although in 
immunohistochemistry experiments Sox9a was localized to the nucleus, and 
	   29	  
in data not shown, Ewsa also was seen in the nucleus, both experiments 
were conducted separately therefore it remains unclear if Ewsa and Sox9 are 
co-localizing on a specific region on the chromatin. Furthermore 
immunohistochemistry would not be able to elucidate if co-localization 
occurred on a regulatory locus of a Sox9 transcriptional target. Given that 
SOX9 requires dimerization for transcriptional activation [31], and that EWS 
biochemically binds to SOX9 [10], it is possible that upstream modifications 
or the presence of other protein factors can act as a switch to allow an EWS-
SOX9 dimerization event which inhibits target gene transcriptional activation 
on the regulatory locus of the target gene. This could explain why there were 
an increased number of cells expressing Ctgfa in MZ ewsa/ewsa rather than 
an increase in protein levels. The role of Ewsa may be to simply inhibit Ctgf 
production during a critical period of chondrocyte differentiation and not 
necessarily to end all normal Sox9-activated transcription of ctgfa.  
We previously reported deformations in the craniofacial cartilage of MZ 
ewsa/ewsa mutant zebrafish[10]. These were described as positional shifts in 
structures compared to the same structure in both wt/wt adult fish and in 
embryos at 4dpf. The time of the start of these deformation remains 
unknown. In this report we measured skeletal deformations as dimensional 
changes in an individual structure at 4dpf and noted the increase in severity 
by 6dpf (fig. 3). These deformations appear to me separate from the 
positional shifts described before. Even so, we have discovered that these 
deformations take place during endochondrial ossification. CTGF is involved 
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in ECM production and skeletal deformations occur with the overexpression 
of CTGF [14, 32]. Furthermore CTGF has been reported to be involved in 
chondrocyte proliferation [33]. Indeed, we have previously shown the 
craniofacial cartilage of MZ ewsa/ewsa mutants which contained a higher 
number of chondrocytes at 4dpf than wt/wt individuals [10]. As mentioned 
above, MZ ewsa/ewsa mutant Ctgf is increased in the craniofacial cartilage, 
therefore we propose that the misregulation of Ctgf is leading to these 
deformations through two ways; ECM overproduction inhibiting normal 
chondrocyte stacking, which then would affect the length of a structure, and 
the over-proliferation of chondrocytes which then could affect the width of a 
structure. Studies tracking ECM production in both wt/wt and MZ ewsa/ewsa 
would help to clarify this process.  
In late stages of bone formation, the proteins expressed to promote 
chondrocytes mature to the hypertrophic state, must cease and express high 
levels of VEGF, HIF1 and other factors to induce angiogenesis for vascular 
invasion into the bone tissue [34]. Since EWS is involved in regulating 
chondrocyte maturation, EWS may play a role in vascular invasion as well. 
To elucidate the role of EWS in this process we have turned to the axial 
vasculature of the zebrafish as a model of vasculogenesis. The development 
of intersegmental vessels (ISVs) is an angiogenic process arising from 
preexisting dorsal aortal (DA) cells while the development of the DA, 
posterior cardinal vein (PCV), caudal vein (CV) and caudal artery (CA) 
represent vasculogenesis.  In the MZ ewsa/ewsa mutant fish we discovered 
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perturbations in both processes suggesting that similarly, the process in 
bone vascular invasion is also perturbed. This is the first report to suggest 
that endogenous EWS has a role in normal vascular endothelial expression 
of Sox9 and Ctgf .  Yet since it is still unclear if the loss of ctgfa signal in our 
MZ ewsa/ewsa mutants (figs. 16, 17) is due to loss of expression or loss of 
vascular structures, the immunohistochemistry experiment must be repeated 
with staining for a known vascular marker. WGA and DAPI staining produce 
some evidence of tube-like structures where there is a loss of Sox9 or Ctgf 
signal .Also blood flow can be observed in live MZ ewsa/ewsa embryos, 
giving evidence that vascular structure exists, but it is possible that the 
endothelial cells of the mutant are not expressing Ctgf or Sox9.  It is known 
the CTGF promotes vascular endothelial cell migration and proliferation in 
vitro, and promotes angiogenesis in vivo [18], but at high doses CTGF is 
found to inhibit VEGF and inhibit angiogenesis [19]. We have shown in this 
and our previous report that loss of ewsa leads to Ctgf overexpression 
therefore we propose that this overexpression could be the inhibiting 
mechanism not only for angiogenesis but also for vasculogenesis as well. 
Interestingly, the CTGF/VEGF angiogenic inhibitory complex can be rescued 
by the cleavage of CTGF by matrix metalloproteinase 9 (MMP9)[19] which is 
antagonized by thrombospondin 2 (TSP2) [35]. Furthermore, it has been 
shown that EWS/FLI1 inhibits the expression of thrombospondins. Therefore 
it is plausible that during the human pathology of Ewing’s sarcoma, the loss 
of function of endogenous EWS may lead to CTGF overexpression which in 
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turn inhibits VEGF, which cannot be rescued due to the inhibition of TSPs by 
the fusion protein EWS/FLI1. There are a multitude of pathways to regulate 
both VEGF and CTGF so the ramifications of CTGF overexpression in the 
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Figure 15. Sox9a is expressed in 4dpf embryo facial cartilage.  
Immunohistochemistry of wild-type (WT) and maternal zygotic (MZ) mutant Meckel’s 
cartilage and ceratohyal cartilage at 4dpf with Sox9a showing no change in Sox9a 




Figure 16. Sox9b not expressed in wild-type or mutant embryo facial cartilage.  
Immunohistochemistry of wild-type (WT) and maternal zygotic (MZ) mutant Meckel’s 
cartilage and ceratohyal cartilage at 4dpf with anti-Sox9b antibodies show that there is 
no change in the lack of Sox9b expression between WT and MT. Antibody dilution 
1:500.  
 
	   38	  
 
 
Figure 17. Sox9a is expressed in 5dpf embryo facial cartilage. 
Immunohistochemistry of wild-type (WT) and maternal zygotic (MZ) mutant Meckel’s 
cartilage and ceratohyal cartilage at 5dpf with Sox9a showing no change in Sox9a 





 Figure 18. Sox9a expressed in 6dpf facial cartilage.  Immunohistochemistry of wild-
type (WT) and maternal zygotic (MZ) mutant Meckel’s cartilage and ceratohyal cartilage 
at 6dpf with Sox9a (A.) and Sox9b (B.) show that there is no change in Sox9a 
expression between WT and MT. Sox9b lacks expression in both WT and MT Meckel’s 
cartilage, ceratohyal cartilage (B), hyomandibular cartilage, and palatoquadrate 
cartilage (C). α-Sox9a and α-Sox9b dilutions 1:500. 
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Figure 19. Sox9b lacks expression in 6dpf facial cartilage.  Immunohistochemistry 
of wild-type (WT) and maternal zygotic (MZ) mutant Meckel’s cartilage and ceratohyal 
cartilage at 6dpf with antibodies against Sox9b show that there is no change in 
expression between WT and MT. Sox9b lacks expression in both WT and MT Meckel’s 
cartilage and ceratohyal cartilage. α-Sox9b dilutions 1:500. 
 
 
Figure 20. Ctgf is overexpressed in MZ ewsa mutant facial cartilage at 4dpf. 
Immunohistochemistry of wild-type (WT) and maternal zygotic (MZ) at 4dpf show a 
significantly increased number of chondrocytes expressing Ctgf as seen in the 
hyomandibular and palatoquadrate cartilages hm, hyomandibular cartilage; pq, 
palatoquadrate cartilage. Antibody dilution 1:1000. 
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Figure 21. Ctgf is overexpressed in MZ ewsa mutant facial cartilage at 6dpf. 
Immunohistochemistry of wild-type (WT) and maternal zygotic (MZ) at 6dpf show 
continued increase in the number of chondrocytes expressing Ctgf as seen in the 
hyomandibular and palatoquadrate cartilages. hm, hyomandibular cartilage; pq, 
palatoquadrate cartilage. Antibody dilution 1:1000.  
 
